Reuptake inhibitors of dopamine, noradrenaline, and serotonin

Handbook of Experimental Pharmacology

Volumn 209, Issue , 2012, Pages 339-347

  Kintscher, Ulrich ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Appetite control; Monoamines With best regards; Reuptake inhibitors; Ulrich Kintscher

Indexed keywords

5 METHYLURAPIDIL; AMFEBUTAMONE; AMFEBUTAMONE PLUS NALTREXONE; AMFEBUTAMONE PLUS ZONISAMIDE; AMINOREX; AMPHETAMINE; DOPAMINE; FENFLURAMINE; NORADRENALIN; PHENTERMINE; PLACEBO; SEROTONIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN RECEPTOR; SIBUTRAMINE; TESOFENSINE; ADRENERGIC RECEPTOR AFFECTING AGENT; ANOREXIGENIC AGENT; DOPAMINE UPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR;

APPETITE; ARTICLE; CARDIOVASCULAR DISEASE; CONSTIPATION; DEPRESSION; DIARRHEA; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; FOOD INTAKE; HARD FECES; HEART ARREST; HEART INFARCTION; HUMAN; INSOMNIA; NAUSEA; NONHUMAN; OBESITY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RISK BENEFIT ANALYSIS; TREATMENT DURATION; TREATMENT OUTCOME; VALVULAR HEART DISEASE; WEIGHT REDUCTION; XEROSTOMIA; ANIMAL; DRUG EFFECT; METABOLISM; PATHOPHYSIOLOGY; PSYCHOLOGICAL ASPECT; REVIEW; RISK ASSESSMENT;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; APPETITE DEPRESSANTS; APPETITE REGULATION; DOPAMINE UPTAKE INHIBITORS; HUMANS; NOREPINEPHRINE; OBESITY; RISK ASSESSMENT; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84856348889     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/978-3-642-24716-3_15     Document Type: Article

References (47)

1. Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM2008) Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet 372:1906-1913
2. Axel AM, Mikkelsen JD, Hansen HH2010) Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of alpha1 adrenoceptor and dopamine D1 receptor pathways in the diet-induced obese rat. Neuropsychopharmacology 35:1464-1476
3. Bello NT, Liang NC2011) The use of serotonergic drugs to treat obesity - is there any hope? Drug Des Devel Ther 5:95-109
4. Birkenfeld AL, Schroeder C, Boschmann M, Tank J, Franke G, Luft FC, Biaggioni I, Sharma AM, Jordan J2002) Paradoxical effect of sibutramine on autonomic cardiovascular regulation. Circulation 106:2459-2465 (Pubitemid 35278802)
5. Bray GA, Greenway FL1999) Current and potential drugs for treatment of obesity. Endocr Rev 20:805-875 (Pubitemid 30647075)
6. Burcelin R, Uldry M, Foretz M, Perrin C, Dacosta A, Nenniger-Tosato M, Seydoux J, Cotecchia S, Thorens B2004) Impaired glucose homeostasis in mice lacking the alpha1b-adrenergic receptor subtype. J Biol Chem 279:1108-1115 (Pubitemid 38082632)
7. Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heiligenstein JH, Morin SM, Gehlert DR, Perry KW2002) Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 27:699-711 (Pubitemid 35335888)
8. Clifford PS, Davis KW, Elliott AE, Wellman PJ2007) Effects of ICV administration of the alpha1A-adrenoceptor antagonist 5-methylurapidil on concurrent measures of eating and locomotion after cocaine in the rat. Life Sci 81:1059-1065 (Pubitemid 47418844)
9. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, Schaff HV1997) Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 337:581-588 (Pubitemid 27360757)
10. Fishman AP1999) Aminorex to fen/phen: an epidemic foretold. Circulation 99:156-161 (Pubitemid 29035970)
11. Glick SD, Haskew RE, Maisonneuve IM, Carlson JN, Jerussi TP2000) Enantioselective behavioral effects of sibutramine metabolites. Eur J Pharmacol 397:93-102 (Pubitemid 30323815)
12. Goldman CK, Marino L, Leibowitz SF1985) Postsynaptic alpha 2-noradrenergic receptors mediate feeding induced by paraventricular nucleus injection of norepinephrine and clonidine. Eur J Pharmacol 115:11-19 (Pubitemid 16233354)
13. Greenway FL, Dunayevich E, Tollefson G, Erickson J, Guttadauria M, Fujioka K, Cowley MA2009a) Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo. J Clin Endocrinol Metab 94:4898-4906
14. Greenway FL, Fujioka K, Plodkowski RA, Mudaliar S, Guttadauria M, Erickson J, Kim DD, Dunayevich E2010) Effect of naltrexone plus bupropion on weight loss in overweight and obese adultsCOR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 376:595-605
15. Greenway FL, Whitehouse MJ, Guttadauria M, Anderson JW, Atkinson RL, Fujioka K, Gadde KM, Gupta AK, O'Neil P, Schumacher D, Smith D, Dunayevich E, Tollefson GD, Weber E, Cowley MA2009b) Rational design of a combination medication for the treatment of obesity. ObesitySilver Spring) 17:30-39 (Pubitemid 50324544)
16. Greiser E1973) Epidemiologic studies on the relation between use of appetite depressants and primary vascular pulmonary hypertension. InternistBerl) 14:437-442
17. Hadler AJ1967) Studies of aminorex, a new anorexigenic agent. J Clin Pharmacol J New Drugs 7:296-302
18. Haenisch B, Bonisch H2011) Depression and antidepressants: insights from knockout of dopamine, serotonin or noradrenaline re-uptake transporters. Pharmacol Ther 129:352-368
19. Hansen DL, Toubro S, Stock MJ, Macdonald IA, Astrup A1998) Thermogenic effects of sibutramine in humans. Am J Clin Nutr 68:1180-1186 (Pubitemid 28550946)
20. Hansen HH, Hansen G, Tang-Christensen M, Larsen PJ, Axel AM, Raben A, Mikkelsen JD2010) The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: comparison to sibutramine and rimonabant. Eur J Pharmacol 636:88-95
21. Hein L2006) Adrenoceptors and signal transduction in neurons. Cell Tissue Res 326:541-551 (Pubitemid 44435825)
22. Jackson HC, Bearham MC, Hutchins LJ, Mazurkiewicz SE, Needham AM, Heal DJ1997) Investigation of the mechanisms underlying the hypophagic effects of the 5-HT and noradrenaline reuptake inhibitor, sibutramine, in the rat. Br J Pharmacol 121:1613-1618 (Pubitemid 27343387)
23. James WP, Caterson ID, Coutinho W, Finer N, Van Gaal LF, Maggioni AP, Torp-Pedersen C, Sharma AM, Shepherd GM, Rode RA, Renz CL2010) Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 363:905-917
24. Jordan J, Scholze J, Matiba B, Wirth A, Hauner H, Sharma AM2005) Influence of Sibutramine on blood pressure: evidence from placebo-controlled trials. Int J ObesLond) 29:509-516 (Pubitemid 40592993)
25. Katsiki N, Hatzitolios AI, Mikhailidis DP2011) Naltrexone sustained-releaseSR) + bupropion SR combination therapy for the treatment of obesity: 'A new kid on the block'? Ann Med 43:249-258
26. Leibowitz SF1970a) Hypothalamic beta-adrenergic "satiety" system antagonizes an alphaadrenergic "hunger" system in the rat. Nature 226:963-964
27. Leibowitz SF1970b) Reciprocal hunger-regulating circuits involving alpha- and beta-adrenergic receptors located, respectively, in the ventromedial and lateral hypothalamus. Proc Natl Acad Sci USA 67:1063-1070
28. Leibowitz SF, Brown O, Tretter JR, Kirschgessner A1985) Norepinephrine, clonidine, and tricyclic antidepressants selectively stimulate carbohydrate ingestion through noradrenergic system of the paraventricular nucleus. Pharmacol Biochem Behav 23:541-550 (Pubitemid 16191747)
29. Lesses MF, Myerson A1994) Human autonomic pharmacology. XVI. Benzedrine sulfate as an aid in the treatment of obesity. 1938. Obes Res 2:286-292
30. Li Z, Maglione M, Tu W, Mojica W, Arterburn D, Shugarman LR, Hilton L, Suttorp M, Solomon V, Shekelle PG, Morton SC2005) Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 142:532-546
31. Lucas JJ, Yamamoto A, Scearce-Levie K, Saudou F, Hen R1998) Absence of fenfluramineinduced anorexia and reduced c-Fos induction in the hypothalamus and central amygdaloid complex of serotonin 1B receptor knock-out mice. J Neurosci 18:5537-5544 (Pubitemid 28311968)
32. Padwal RS, Majumdar SR2007) Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 369:71-77 (Pubitemid 46027230)
33. Parsons AC, Shraim M, Inglis J, Aveyard P, Hajek P2009) Interventions for preventing weight gain after smoking cessation. Cochrane Database Syst Rev: CD006219
34. Rothman RB, Baumann MH2002) Therapeutic and adverse actions of serotonin transporter substrates. Pharmacol Ther 95:73-88
35. Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, Partilla JS2001) Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 39:32-41
36. Rothman RB, Clark RD, Partilla JS, Baumann MH2003)+)-Fenfluramine and its major metabolite,+)-norfenfluramine, are potent substrates for norepinephrine transporters. J Pharmacol Exp Ther 305:1191-1199 (Pubitemid 36617998)
37. Rucker D, Padwal R, Li SK, Curioni C, Lau DC2007) Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 335:1194-1199 (Pubitemid 350273303)
38. Samanin R, Garattini S1993) Neurochemical mechanism of action of anorectic drugs. Pharmacol Toxicol 73:63-68 (Pubitemid 23278474)
39. Schildkraut JJ1965) The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 122:509-522
40. Sulzer D, Sonders MS, Poulsen NW, Galli A2005) Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol 75:406-433 (Pubitemid 40834286)
41. Terry P, Gilbert DB, Cooper SJ1995) Dopamine receptor subtype agonists and feeding behavior. Obes Res 3(Suppl 4):515S-523S
42. Tsujii S, Bray GA1992) Food intake of lean and obese Zucker rats following ventricular infusions of adrenergic agonists. Brain Res 587:226-232
43. Valentino MA, Lin JE, Waldman SA2010) Central and peripheral molecular targets for antiobesity pharmacotherapy. Clin Pharmacol Ther 87:652-662
44. Vickers SP, Clifton PG, Dourish CT, Tecott LH1999) Reduced satiating effect of d-fenfluramine in serotonin 5-HT(2C) receptor mutant mice. PsychopharmacologyBerl) 143:309-314 (Pubitemid 29204986)
45. Weintraub M, Hasday JD, Mushlin AI, Lockwood DH1984) A double-blind clinical trial in weight control. Use of fenfluramine and phentermine alone and in combination. Arch Intern Med 144:1143-1148 (Pubitemid 14121061)
46. Wellman PJ, Davies BT, Morien A, McMahon L1993) Modulation of feeding by hypothalamic paraventricular nucleus alpha 1- and alpha 2-adrenergic receptors. Life Sci 53:669-679
47. Wirth A, Krause J2001) Long-term weight loss with sibutramine: a randomized controlled trial. JAMA 286:1331-1339 (Pubitemid 33015524)